Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2014, specifically dated June 2, 2014. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event reported is the U.S. Food and Drug Administration (FDA) agreement with the Company's study protocol for a Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA protocol agreement. The filing does not contain specific financial guidance, outlook projections, or a detailed discussion of risks and contingencies beyond the context of the clinical trial progress.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the Phase II trial design.
- Confirm the specific indications and patient population for the CF102 advanced liver cancer trial.
- Review subsequent filings for updates on trial initiation and enrollment status.